Heba M Bintalib1,2,3, David M Lowe4,5, Gaia Mancuso6, Georgia Gkrepi7, Suranjith L Seneviratne5, Siobhan O Burns4,5, John R Hurst1. 1. UCL Respiratory, University College London, London, UK. 2. Department of Respiratory Care, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia. 3. King Abdullah International Medical Research Center, Jeddah, Saudi Arabia. 4. Institute of Immunity and Transplantation, University College London, London, UK. 5. Department of Immunology, Royal Free London NHS Foundation Trust, London, UK. 6. Unit of Immunology, Rheumatology, Allergy, and Rare Diseases (UnIRAR), Vita-Salute San Raffaele University, Milan, Italy. 7. Respiratory Medicine Department, University Hospital of Ioannina, Ioannina, Greece.
Abstract
Aim: The aim of the study was to evaluate the response in lung function to different treatment regimens for common variable immunodeficiency patients with granulomatous lymphocytic interstitial lung disease (GLILD). Method: A longitudinal retrospective cohort study was carried out. Patients were divided into three groups. To assess the response to different treatments, we compared baseline lung function with post-treatment tests. Results: 14 patients with GLILD were included, seven of whom were treated with acute corticosteroids for a mean duration of 132±65 days. Spirometry results were unchanged, but there was a significant improvement in diffusing capacity of the lung for carbon monoxide (D LCO)% and transfer coefficient of the lung for carbon monoxide (K CO)% (median change in D LCO%=7%, p=0.04, and K CO%=13%, p=0.02). Relapse occurred in three out of seven patients. Five patients were treated with long-term mycophenolate mofetil (MMF) with/without corticosteroids for a mean duration of 1277±917 days. No changes were found in spirometry; however, there was a significant increase in D LCO% and K CO% (median change in each of D LCO% and K CO%=10%, p=0.04). Four patients on steroids with MMF successfully weaned the prednisone dose over 12 months. Four patients never received immunosuppression therapy. A significant decline was found in their lung function assessed over 7.5 years. The median reduction in the forced vital capacity (FVC)%, forced expiratory volume in 1 s (FEV1)% and D LCO% was 15%, 7% and 15%, equivalent to 2%, 1% and 2% per year, respectively. Conclusion: Corticosteroids improve gas transfer in GLILD, but patients often relapse. The use of MMF was associated with long-term effectiveness in GLILD and permits weaning of corticosteroids. A delay in initiating and continuing maintenance treatment could lead to disease progression.
Aim: The aim of the study was to evaluate the response in lung function to different treatment regimens for common variable immunodeficiency patients with granulomatous lymphocytic interstitial lung disease (GLILD). Method: A longitudinal retrospective cohort study was carried out. Patients were divided into three groups. To assess the response to different treatments, we compared baseline lung function with post-treatment tests. Results: 14 patients with GLILD were included, seven of whom were treated with acute corticosteroids for a mean duration of 132±65 days. Spirometry results were unchanged, but there was a significant improvement in diffusing capacity of the lung for carbon monoxide (D LCO)% and transfer coefficient of the lung for carbon monoxide (K CO)% (median change in D LCO%=7%, p=0.04, and K CO%=13%, p=0.02). Relapse occurred in three out of seven patients. Five patients were treated with long-term mycophenolate mofetil (MMF) with/without corticosteroids for a mean duration of 1277±917 days. No changes were found in spirometry; however, there was a significant increase in D LCO% and K CO% (median change in each of D LCO% and K CO%=10%, p=0.04). Four patients on steroids with MMF successfully weaned the prednisone dose over 12 months. Four patients never received immunosuppression therapy. A significant decline was found in their lung function assessed over 7.5 years. The median reduction in the forced vital capacity (FVC)%, forced expiratory volume in 1 s (FEV1)% and D LCO% was 15%, 7% and 15%, equivalent to 2%, 1% and 2% per year, respectively. Conclusion: Corticosteroids improve gas transfer in GLILD, but patients often relapse. The use of MMF was associated with long-term effectiveness in GLILD and permits weaning of corticosteroids. A delay in initiating and continuing maintenance treatment could lead to disease progression.
Authors: Francisco A Bonilla; Isil Barlan; Helen Chapel; Beatriz T Costa-Carvalho; Charlotte Cunningham-Rundles; M Teresa de la Morena; Francisco J Espinosa-Rosales; Lennart Hammarström; Shigeaki Nonoyama; Isabella Quinti; John M Routes; Mimi L K Tang; Klaus Warnatz Journal: J Allergy Clin Immunol Pract Date: 2015-11-07
Authors: Julie Morisset; Kerri A Johannson; Eric Vittinghoff; Carlos Aravena; Brett M Elicker; Kirk D Jones; Charlene D Fell; Helene Manganas; Bruno-Pierre Dubé; Paul J Wolters; Harold R Collard; Christopher J Ryerson; Brett Ley Journal: Chest Date: 2016-11-03 Impact factor: 9.410
Authors: Aryeh Fischer; Kevin K Brown; Roland M Du Bois; Stephen K Frankel; Gregory P Cosgrove; Evans R Fernandez-Perez; Tristan J Huie; Mahalakshmi Krishnamoorthy; Richard T Meehan; Amy L Olson; Joshua J Solomon; Jeffrey J Swigris Journal: J Rheumatol Date: 2013-03-01 Impact factor: 4.666
Authors: John R Hurst; Nisha Verma; David Lowe; Helen E Baxendale; Stephen Jolles; Peter Kelleher; Hilary J Longhurst; Smita Y Patel; Elisabetta A Renzoni; Clare R Sander; Gerard R Avery; Judith L Babar; Matthew S Buckland; Siobhan Burns; William Egner; Mark M Gompels; Pavels Gordins; Jamanda A Haddock; Simon P Hart; Grant R Hayman; Richard Herriot; Rachel K Hoyles; Aarnoud P Huissoon; Joseph Jacob; Andrew G Nicholson; Doris M Rassl; Ravishankar B Sargur; Sinisa Savic; Suranjith L Seneviratne; Michael Sheaff; Prashantha M Vaitla; Gareth I Walters; Joanna L Whitehouse; Penny A Wright; Alison M Condliffe Journal: J Allergy Clin Immunol Pract Date: 2017-03-25
Authors: Olivia A C Lamers; Bas M Smits; Helen Louisa Leavis; Godelieve J de Bree; Charlotte Cunningham-Rundles; Virgil A S H Dalm; Hsi-En Ho; John R Hurst; Hanna IJspeert; Sabine M P J Prevaes; Alex Robinson; Astrid C van Stigt; Suzanne Terheggen-Lagro; Annick A J M van de Ven; Klaus Warnatz; Janneke H H M van de Wijgert; Joris van Montfrans Journal: Front Immunol Date: 2021-04-15 Impact factor: 7.561